Eli Lilly Shares Surge Following FDA Approval of Foundayo
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: NASDAQ.COM
- FDA Drug Approval: Eli Lilly's oral GLP-1 therapy Foundayo (orforglipron) received FDA approval, demonstrating a mean weight loss of 12.4% and cardiovascular benefits in clinical trials, which is expected to significantly expand the underpenetrated patient population and reinforce the company's leadership in the obesity market.
- Stock Price Rebound: Following the FDA approval news, Eli Lilly shares surged 3.8% in the last trading session to close at $954.52, reflecting strong market confidence in its new drug despite an 8.7% decline over the past four weeks.
- Strong Earnings Forecast: The company is expected to report quarterly earnings of $7.53 per share, representing a year-over-year increase of 125.5%, with revenues projected to reach $17.66 billion, up 38.7% from the previous year, indicating robust growth potential.
- Upward Earnings Revision: Over the past 30 days, the consensus EPS estimate for Eli Lilly has been revised 2.3% higher, and such positive earnings estimate revisions are typically correlated with stock price appreciation, suggesting investors should monitor its future performance closely.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 931.090
Low
950.00
Averages
1192
High
1500
Current: 931.090
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's New Drug Approval May Boost Stock Recovery
- FDA Drug Approval: On April 1, Eli Lilly announced that the FDA approved its oral GLP-1 weight-loss drug Foundayo, marking a significant milestone that strengthens its leadership in the rapidly growing weight-loss market and is expected to attract more patients who prefer oral medications.
- Competitive Advantage: Unlike its competitor oral Wegovy, Foundayo can be taken without food or water restrictions and costs as low as $149 per month, significantly reducing the financial burden on patients, which could expand market share and boost sales.
- New Drug Potential: Although Foundayo's efficacy is lower than Zepbound, its convenience and cost advantages are likely to garner significant attention in the weight-loss drug market, while Eli Lilly is also developing additional weight-loss medications to further penetrate the market.
- Long-term Investment Value: Eli Lilly is expanding its product line through licensing deals and acquisitions, heavily investing in artificial intelligence for innovation, and improving its margins in recent years, making its stock attractive for long-term investors despite a 13% decline this year.
See More
Indian Textile Industry Faces New Challenges Amid Iran War
- Export Decline: India's textile exports from April 2025 to February 2026 totaled $29.5 billion, a slight drop from $29.8 billion the previous year, indicating the fragility of recovery in an industry aiming for $100 billion in exports by 2030.
- Rising Costs: The Iran war has driven raw material and packaging costs up, with polyester prices increasing over 40% since the conflict began, complicating companies' ability to pass costs onto customers and impacting production and profitability.
- Weak Demand: Although tariff relief from the U.S. provided temporary respite, industry leaders warn that a prolonged war could dampen U.S. consumer demand, leading to declining sales and rising inventories, posing significant challenges for retailers.
- Production Cuts: Companies like Filatex have already reduced production by 25% and are awaiting demand recovery, with widespread concerns that failure to pass on costs could lead to larger-scale production cuts, further affecting employment and economic growth.
See More
NXERA PHARMA CO LTD - POTENTIAL TO RECEIVE UP TO $694 MILLION IN MILESTONES AND TIERED ROYALTIES FROM LILLY AGREEMENT
Company Announcement: NERAPHARMA COLTD has announced eligibility for up to $694 million in milestone payments.
Partnership Details: The agreement involves collaboration with Royal Ties under the Lilly agreement.
See More
NXERA PHARMA CO LTD: PAYMENT DETAILS REMAIN CONFIDENTIAL IN AGREEMENT WITH LILLY.
- Company Overview: NERAPHARMA COLTD is involved in a financial agreement with Lilly.
- Payment Details: The payment amount related to the agreement remains undisclosed.
See More
NXERA PHARMA CO REACHES SECOND DEVELOPMENT MILESTONE IN PARTNERSHIP WITH ELI LILLY FOCUSING ON METABOLIC DISEASES
Collaboration Announcement: NERAPHARMA has achieved a significant milestone by collaborating with Eli Lilly to develop treatments targeting metabolic diseases.
Focus on Metabolic Diseases: The partnership aims to address various metabolic disorders, leveraging both companies' expertise in pharmaceutical development.
See More
Pharma Giants Compete: Novo Nordisk vs Eli Lilly
- Market Share Competition: Novo Nordisk faces competition in the U.S. GLP-1 drug market from Eli Lilly, which currently holds a 60% market share, leading to a decline in Novo's market position and impacting its future revenue growth potential.
- Product Innovation and Sales: Novo's oral Wegovy drug has been approved and shows rapid market uptake, with initial data indicating that 36% of users are new to GLP-1 drugs, potentially expanding the patient base and enhancing the company's competitiveness in the fast-growing weight loss drug market.
- Eli Lilly's Strong Performance: Eli Lilly achieved over $36 billion in revenue last year through Mounjaro and Zepbound, demonstrating robust growth in the weight loss drug market, and its newly approved oral drug Foundayo may further strengthen its market position.
- Investment and Future Outlook: While Novo's lower valuation may attract investors, Eli Lilly's strong performance in the oral GLP-1 market and the launch of new products could give it an edge in future market competition, affecting Novo's growth prospects.
See More
Eli Lilly's New Drug Approval May Boost Stock Recovery
- FDA Drug Approval: On April 1, Eli Lilly announced that the FDA approved its oral GLP-1 weight-loss drug Foundayo, marking a significant milestone that strengthens its leadership in the rapidly growing weight-loss market and is expected to attract more patients who prefer oral medications.
- Competitive Advantage: Unlike its competitor oral Wegovy, Foundayo can be taken without food or water restrictions and costs as low as $149 per month, significantly reducing the financial burden on patients, which could expand market share and boost sales.
- New Drug Potential: Although Foundayo's efficacy is lower than Zepbound, its convenience and cost advantages are likely to garner significant attention in the weight-loss drug market, while Eli Lilly is also developing additional weight-loss medications to further penetrate the market.
- Long-term Investment Value: Eli Lilly is expanding its product line through licensing deals and acquisitions, heavily investing in artificial intelligence for innovation, and improving its margins in recent years, making its stock attractive for long-term investors despite a 13% decline this year.
See More
Indian Textile Industry Faces New Challenges Amid Iran War
- Export Decline: India's textile exports from April 2025 to February 2026 totaled $29.5 billion, a slight drop from $29.8 billion the previous year, indicating the fragility of recovery in an industry aiming for $100 billion in exports by 2030.
- Rising Costs: The Iran war has driven raw material and packaging costs up, with polyester prices increasing over 40% since the conflict began, complicating companies' ability to pass costs onto customers and impacting production and profitability.
- Weak Demand: Although tariff relief from the U.S. provided temporary respite, industry leaders warn that a prolonged war could dampen U.S. consumer demand, leading to declining sales and rising inventories, posing significant challenges for retailers.
- Production Cuts: Companies like Filatex have already reduced production by 25% and are awaiting demand recovery, with widespread concerns that failure to pass on costs could lead to larger-scale production cuts, further affecting employment and economic growth.
See More
NXERA PHARMA CO LTD - POTENTIAL TO RECEIVE UP TO $694 MILLION IN MILESTONES AND TIERED ROYALTIES FROM LILLY AGREEMENT
Company Announcement: NERAPHARMA COLTD has announced eligibility for up to $694 million in milestone payments.
Partnership Details: The agreement involves collaboration with Royal Ties under the Lilly agreement.
See More
NXERA PHARMA CO LTD: PAYMENT DETAILS REMAIN CONFIDENTIAL IN AGREEMENT WITH LILLY.
- Company Overview: NERAPHARMA COLTD is involved in a financial agreement with Lilly.
- Payment Details: The payment amount related to the agreement remains undisclosed.
See More
NXERA PHARMA CO REACHES SECOND DEVELOPMENT MILESTONE IN PARTNERSHIP WITH ELI LILLY FOCUSING ON METABOLIC DISEASES
Collaboration Announcement: NERAPHARMA has achieved a significant milestone by collaborating with Eli Lilly to develop treatments targeting metabolic diseases.
Focus on Metabolic Diseases: The partnership aims to address various metabolic disorders, leveraging both companies' expertise in pharmaceutical development.
See More
Pharma Giants Compete: Novo Nordisk vs Eli Lilly
- Market Share Competition: Novo Nordisk faces competition in the U.S. GLP-1 drug market from Eli Lilly, which currently holds a 60% market share, leading to a decline in Novo's market position and impacting its future revenue growth potential.
- Product Innovation and Sales: Novo's oral Wegovy drug has been approved and shows rapid market uptake, with initial data indicating that 36% of users are new to GLP-1 drugs, potentially expanding the patient base and enhancing the company's competitiveness in the fast-growing weight loss drug market.
- Eli Lilly's Strong Performance: Eli Lilly achieved over $36 billion in revenue last year through Mounjaro and Zepbound, demonstrating robust growth in the weight loss drug market, and its newly approved oral drug Foundayo may further strengthen its market position.
- Investment and Future Outlook: While Novo's lower valuation may attract investors, Eli Lilly's strong performance in the oral GLP-1 market and the launch of new products could give it an edge in future market competition, affecting Novo's growth prospects.
See More
